Immunology
Latest News
July 2nd 2025
The MEGA-J study reveals CT-P13's long-term safety and effectiveness in treating inflammatory bowel disease and rheumatoid arthritis, with minimal adverse reactions.
Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis
1.0 Credit / Immunology, Neurology
View More
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
1 Credit / Cardiology, Neurology
View More
From Treatment to Prevention: Navigating the Expanding Hereditary Angioedema Treatment Landscape
August 13, 2025 | 1:00 PM & 8:00 PM EDT
View More
Innovations in Hidradenitis Suppurativa Treatment: Navigating the Evolving Landscape for Managed Care Professi...
August 19, 2025 | 1:00 PM & 8:00 PM ET
View More
Optimizing Outcomes in Myasthenia Gravis: Therapeutic Advances and Value-Based Care Models
August 21, 2025 | 1:00 PM ET & 8:00 PM ET
View More
Managed Care Insights on the Advances in the Eosinophilic Esophagitis Treatment Landscape
1.0 Credit / Gastroenterology, Immunology, Rare Diseases
View More
Managing Patients With COPD: Evidence-Based Care and Optimizing Value of New and Emerging Targeted Therapies
1.0 Credit / Immunology, Pulmonology/Respiratory
View More
Managed Care Approaches to Individualize Treatment of Hereditary Angioedema
1.0 Credit / Immunology
View More
From Strict Avoidance to Tailored Therapies: Transforming Food Allergy Care
1.5 Credits / Allergy, Immunology
View More
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
View More
Leveraging Biologics and Immunotherapies in the Management of Food Allergies
1.5 Credits / Immunology, Allergy
View More
Reflecting on the Real-World Use of Biologic Therapy in Asthma Management
1.5 Credits / Immunology, Pulmonology
View More
Targeting Chronic Rhinosinusitis With Nasal Polyps With Biologics: Optimizing Outcomes and Reducing Health Car...
1.5 Credits / Immunology
View More
Emerging Treatment Options for Inflammatory Bowel Disease: A Focus on IL-23 Pathway Inhibition
1.5 Credits / Gastroenterology, Immunology
View More
Innovations in Inflammatory Bowel Disease Therapy: How IL-23 Inhibitors Are Shaping Treatment and Managed Care...
1.5 Credits / Gastroenterology, Immunology
View More
The Expanding Therapeutic Landscape in IgA Nephropathy: Applying Evidence-Based Strategies and Guideline Updat...
1.0 Credit / Immunology, Nephrology
View More
The Expanding Therapeutic Landscape in IgA Nephropathy: A Case-Based Exploration of Optimized Patient Outcomes
1.0 Credit / Immunology, Nephrology
View More
More News
Multiple Infliximab Biosimilar Switches Appear Safe, Effective for Patients With IBD
April 20th 2023A retrospective study in Scotland found that multiple successive changes from originator infliximab to biosimilars seem to be safe and effective in patients with inflammatory bowel disease (IBD), irrespective of the number of switches.
FDA Issues Another CRL for Alvotech’s Adalimumab Biosimilar
April 14th 2023In a complete response letter (CRL) for Alvotech, the FDA cited “deficiencies” in the company’s manufacturing facility during a reinspection, further delaying the approval for the ninth adalimumab biosimilar until potentially June 2023.
Real-world Data Show Interchangeability of Rituximab Biosimilar
April 11th 2023A retrospective real-world study assessing patient outcomes related to switching from reference rituximab (Rituxan) to a biosimilar version (Truxima) found that transitioning between the products was safe for patients and did not result in a change in adverse events.
Eye on Pharma: EU Approves High-Concentration Adalimumab Biosimilar; FDA Accepts BLA for HLX02
April 6th 2023The European Union gained another high-concentration adalimumab biosimilar with the approval of Sandoz’ Hyrimoz HCF and the FDA accepted a biologics license application for a trastuzumab biosimilar (HLX02).
Yukon Becomes Tenth Canadian Jurisdiction to Add Biosimilars Switching Policy
March 30th 2023Yukon, 1 of 3 Canadian territories, announced that it will implement a biosimilars switching policy, following Newfoundland and Labrador’s announcement to move forward with a similar policy earlier this week.
Favorable Equivalency Studies of Candidate Biosimilar AVT04 and Reference Ustekinumab
March 27th 2023Posters presented by Alvotech at 2023 American Academy of Dermatology (AAD) annual meeting showcased proven bioequivalence and therapeutic equivalence candidate biosimilar AVT04 and reference ustekinumab (Stelara).
